Artiva Biotherapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Artiva Biotherapeutics advances AlloNK, an allogeneic NK cell therapy, targeting autoimmune diseases and cancers, with initial data expected in the first half of 2025.